当前位置: X-MOL首页全球导师 国内导师 › 杨成斌

个人简介

学习工作经历 2008.9-2012.7 淮南师范学院化学与化工系,获得理学学士学位 2014.5-2015.5 复旦大学化学系,科研助理 2015.9-2018.6 复旦大学化学系,获得理学硕士学位 2018.9-2021.6 复旦大学化学系,获得理学博士学位 2021.6-2024.2 复旦大学药学院,博士后 2024.3起 复旦大学化学系,青年副研究员 获奖情况 复旦大学超级博士后 上海医学院2021年度博士后激励计划 复旦大学“卓越博士生科研促进计划”

研究领域

肿瘤、炎症、代谢类、视网膜等疾病的创新药物发现研究 药物靶标发现研究 生物正交 酶催化小分子合成

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Chengbin Yang, Yi Chen, Tianze Wu, Yunjian Gao, Xiaofeng Liu, Yongtai Yang, Yun Ling, Yu Jia, Mingli Deng*, Jianxin Wang, Yaming Zhou*, Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a Highly Potent PI3K/mTOR Dual Inhibitor for the Treatment of Acute Myeloid Leukemia. Eur. J. Med. Chem. 2023, 258, 115543. Chengbin Yang1, Menghui Wang1, Yimin Gong, Mingli Deng, Yun Ling, Qingquan Li, Jianxin Wang*, Yaming Zhou*, Discovery and Identification of a Novel PI3K Inhibitor with Enhanced CDK2 Inhibition for the Treatment of Triple Negative Breast Cancer. Bioorg. Chem.2023, 140, 106779. Chengbin Yang1, Yimin Gong1, Mingli Deng, Yun Ling, Jianxin Wang*, Yaming Zhou*, Discovery of a Photosensitizing PI3K Inhibitor for Tumor Therapy: Design, Synthesis and in vitro Biological Evaluation. Bioorg. Med. Chem. Lett.2023, 94, 129459. Chengbin Yang, Yimin Gong, Yunjian Gao, Mingli Deng, Xiaofeng Liu, Yongtai Yang, Yun Ling, Yu Jia*, Yaming Zhou*, Design, Synthesis and In Vitro Biological Evaluation of 2-Aminopyridine Derivatives as Novel PI3Kδ Inhibitors for Hematological Cancer. Bioorg. Med. Chem. Lett. 2023, 82, 129152. Ruiqing Xiang1, Mingzhu Lu1, Tianze Wu, Chengbin Yang, Yu Jia, Xiaofeng Liu, Mingli Deng*, Yu Ge, Jun Xu, Tong Cai, Yun Ling, Yaming Zhou*, Discovery of a high potent PIM kinase inhibitor for acute myeloid leukemia based on N-pyridinyl amide scaffold by optimizing the fragments toward to Lys67 and Asp128/Glu171. Eur. J. Med. Chem.2023, 257,115514. Tianze Wu, Yi Chen, Chengbin Yang, Mingzhu Lu, Fang Geng, Jianhua Guo, Yan Pi, Yun Ling, Jun Xu, Tong Cai, Lei Lu & Yaming Zhou*, Systematical Evaluation of the Structure-Cardiotoxicity Relationship of 7-Azaindazole-based PI3K Inhibitors Designed by Bioisosteric Approach. Cardiovasc. Toxicol.2023, 23, 364-376. Yi Chen; Tianze Wu, Chengbin Yang, Mingzhu Lu, Zhenxia Chen, Mingli Deng, Yongtai Yang, Xiaofeng Liu, Yu Jia, Hongyan Wang, Lei Lu, Yun Ling, Yaming Zhou*, A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis via Inhibiting PI3K Pathway in Acute Myeloid Leukemia. PLoS ONE2022, 11, e0277893. Chengbin Yang1, Chenyue Xu1, Zhipeng Li, Yi Chen, Tianze Wu, Hui Hong, Mingzhu Lu, Yu Jia, Yongtai Yang, Xiaofeng Liu, Mingli Deng, Zhenxia Chen, Qingquan Li*, Yun Ling*, Yaming Zhou*, Bioisosteric Replacements of the Indole Moiety for the Development of a Potent and Selective PI3Kδ Inhibitor: Design, Synthesis and Biological Evaluation. Eur. J. Med. Chem.2021, 223, 113661. Chengbin Yang, Mingzhu Lu, Yi Chen, Ruiqing Xiang, Tianze Qiu, Yu Jia, Yongtai Yang, Xiaofeng Liu, Mingli Deng, Yun Ling, Yaming Zhou*, Development of Anti-Breast Cancer PI3K Inhibitors Based on 7-Azaindole Derivatives through Scaffold Hopping: Design, Synthesis and in Vitro Biological Evaluation. Bioorg. Chem.2021, 117, 105405. Chengze Tian, Chengbin Yang, Tianze Wu, Mingzhu Lu, Yi Chen, Yongtai Yang, Xiaofeng Liu, Yun Ling, Mingli Deng, Yu Jia*, Yaming Zhou*, Discovery of Cinnoline Derivatives as Potent PI3K Inhibitors with Antiproliferative Activity. Bioorg. Med. Chem. Lett.2021, 48, 128271. Chengbin Yang#, Xi Zhang#, Yi Wang, Yongtai Yang, Xiaofeng Liu, Mingli Deng, Yu Jia,Yun Ling, Ling-hua Meng*, and Yaming Zhou*, Discovery of a Novel Series of 7‑Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity, ACS Med. Chem. Lett.2017, 8, 875–880.

推荐链接
down
wechat
bug